| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Medicine II, Johannes Gutenberg University, Mainz,
Germany.
Correspondence to Hans-Jürgen Rupprecht, MD, Department of Medicine II, Johannes Gutenberg-University, Langenbeckstr 1, D-55101 Mainz, Germany.
Background—This study was performed
to analyze the influence of either aspirin, ticlopidine, or
their combination on platelet activation and aggregation
parameters after stent implantation.
Methods and Results—Sixty-one patients with successful
implantation of a single Palmaz-Schatz stent in a native
coronary artery were randomly assigned to either group A
(aspirin 300 mg/d+ticlopidine 2x250 mg/d), group B (ticlopidine 2x250
mg/d), or group C (aspirin 300 mg/d). Platelet activation was
evaluated on days 1, 7, and 14 by flow cytometry measurement of
expression of CD62p (p-selectin) and the binding of fibrinogen to the
platelet surface glycoprotein IIb/IIIa receptor.
Platelet aggregation was induced by addition of ADP or collagen.
Differences between treatment groups were compared by ANOVA. Between
days 1 and 14, we observed a significant decrease in collagen-induced
platelet aggregation in group A (62.2±2.5% versus 36.9±3.1%),
whereas an increase was seen in group B (58.3±2.5% versus
67.7±3.2%) and no change was seen in group C
(P<.0001). The ADP-induced aggregation declined
significantly in group A (74.7±1.4% versus 55.3±2.6%), whereas a
delayed reduction was seen in group B (72.0±3.0% versus 52.6±4.2%)
and no change was seen in group C (P=.0017). The CD62p
expression declined significantly in groups A (68.2±2.7% versus
41.3±2.7%) and B (64.8±2.9% versus 39.3±3.5%) but not in group C
(P<.0001). Moreover, the fibrinogen binding decreased
significantly in group A (61.0±4.3% versus 36.3±4.2%) and with
delay in group B (58.3±2.2% versus 39.4±3.0%), whereas no
alterations were seen in group C (P=.012).
Conclusions—Our results demonstrate synergistic and accelerated
platelet inhibitory effects of ticlopidine plus aspirin
in patients after stent implantation compared with a monotherapy with
either ticlopidine or aspirin alone.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Comparison of Antiplatelet Effects of Aspirin, Ticlopidine, or Their Combination After Stent Implantation
Key Words: stents • platelet aggregation inhibitors • aspirin
This article has been cited by other articles:
 |
|
 |
|
  M. S. Sabatine, C. P. Cannon, C. M. Gibson, J. L. Lopez-Sendon, G. Montalescot, P. Theroux, B. S. Lewis, S. A. Murphy, C. H. McCabe, E. Braunwald, et al. Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics: The PCI-CLARITY Study JAMA, September 14, 2005; 294(10): 1224 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schomig, C. Schmitt, A. Dibra, J. Mehilli, C. Volmer, H. Schuhlen, J. Dirschinger, F. Dotzer, J. M. ten Berg, F.-J. Neumann, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel Eur. Heart J., July 2, 2005; 26(14): 1379 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Geiger, L. Teichmann, R. Grossmann, B. Aktas, U. Steigerwald, U. Walter, and R. Schinzel Monitoring of Clopidogrel Action: Comparison of Methods Clin. Chem., June 1, 2005; 51(6): 957 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanderson, J. Emery, T. Baglin, and A.-L. Kinmonth Narrative Review: Aspirin Resistance and Its Clinical Implications Ann Intern Med, March 1, 2005; 142(5): 370 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Tsetis and A-M Belli The role of infrapopliteal angioplasty Br. J. Radiol., December 1, 2004; 77(924): 1007 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Shechter Do statins really interfere with clopidogrel-induced platelet function? Eur. Heart J., March 1, 2004; 25(5): 448 - 448. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamazaki, S. Uchiyama, A. J. Grau, L. Marquardt, and A. Ruf Platelet Function Under Aspirin, Clopidogrel, and Both After Ischemic Stroke: A Case-Crossover Study * Response Stroke, December 1, 2003; 34 (12): e227 - e228. [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Chan, D. J. Moliterno, P. B. Berger, G. W. Stone, P. M. DiBattiste, S. L. Yakubov, S. K. Sapp, K. Wolski, D. L. Bhatt, E. J. Topol, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival: Results from the do tirofiban and reoprogive similar efficacy outcome trial (TARGET) J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1188 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Tcheng and M. E. Campbell Platelet inhibition strategies in percutaneous coronary intervention: Competition or coopetition? J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1196 - 1198. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Leon, C. Ravanat, M. Freund, J.-P. Cazenave, and C. Gachet Differential Involvement of the P2Y1 and P2Y12 Receptors in Platelet Procoagulant Activity Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1941 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shechter, W. C. Lau, L. A. Waskell, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, E. R. Bates, P. B. Watkins, D. G.M. Carville, et al. Atorvastatin and the Ability of Clopidogrel to Inhibit Platelet Aggregation * Response Circulation, June 10, 2003; 107 (22): e210 - e210. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fattorutto, G. Mychaskiw II, and C. Vaughn Massive Hemorrhage During Radiofrequency Ablation of a Pulmonary Neoplasm * Response Anesth. Analg., April 1, 2003; 96(4): 1233 - 1234. [Full Text] [PDF]
|
|
|
|
|
|
J.W. Eikelboom, J.I. Weitz, A. Budaj, F. Zhao, I. Copland, P. Maciejewski, M. Johnston, and S. Yusuf Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes Eur. Heart J., November 2, 2002; 23(22): 1771 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Graff, U. Klinkhardt, V. B. Schini-Kerth, S. Harder, N. Franz, S. Bassus, and C. M. Kirchmaier Close Relationship between the Platelet Activation Marker CD62 and the Granular Release of Platelet-Derived Growth Factor J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 952 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.A. Lanza, F. Andreotti, A. Sestito, A. Sciahbasi, F. Crea, and A. Maseri Platelet aggregability in cardiac syndrome X Eur. Heart J., October 2, 2001; 22(20): 1924 - 1930. [Abstract] [PDF]
|
|
|
|
|
|
S. R. Steinhubl, S. G. Ellis, K. Wolski, A. M. Lincoff, and E. J. Topol Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events : Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial Circulation, March 13, 2001; 103(10): 1403 - 1409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt, D. P. Chew, A. T. Hirsch, P. A. Ringleb, W. Hacke, and E. J. Topol Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery Circulation, January 23, 2001; 103(3): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Tong, H. J. Cloft, G. J. Joseph, O. B. Samuels, and J. E. Dion Abciximab Rescue in Acute Carotid Stent Thrombosis AJNR Am. J. Neuroradiol., October 1, 2000; 21(9): 1750 - 1752. [Abstract] [Full Text]
|
|
|
|
|
|
K. Moshfegh, M. Redondo, F. Julmy, W. A. Wuillemin, M. U. Gebauer, A. Haeberli, and B. J. Meyer Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy J. Am. Coll. Cardiol., September 1, 2000; 36(3): 699 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C I O BROOKES and U SIGWART Taming platelets in coronary stenting: ticlopidine out, clopidogrel in? Heart, December 1, 1999; 82(6): 651 - 652. [Full Text]
|
|
|
|
|
|
M. J. Quinn and D. J. Fitzgerald Ticlopidine and Clopidogrel Circulation, October 12, 1999; 100(15): 1667 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Altman, A. Scazziota, J. Rouvier, and C. Gonzalez Effects of Ticlopidine or Ticlopidine Plus Aspirin on Platelet Aggregation and ATP Release in Normal Volunteers: Why Aspirin Improves Ticlopidine Antiplatelet Activity Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(4): 243 - 246. [Abstract] [PDF]
|
|
|
|
|
|
I. Moussa, M. Oetgen, G. Roubin, A. Colombo, X. Wang, S. Iyer, R. Maida, M. Collins, E. Kreps, and J. W. Moses Effectiveness of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin in Preventing Stent Thrombosis After Coronary Stent Implantation Circulation, May 11, 1999; 99(18): 2364 - 2366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Steinhubl, M. S. Lauer, D. P. Mukherjee, D. J. Moliterno, A. M. Lincoff, S. G. Ellis, and E. J. Topol The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1366 - 1370. [Abstract] [Full Text] [PDF]
|
|